Effects of Intranasal Oxytocin on Emotion Regulation

University of Electronic Science and Technology of China

Status and phase: Unknown; Early Phase 1

Conditions: Healthy

Treatments: Drug: Oxytocin; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03055546

UESTC-neuSCAN-11

Details and patient eligibility

About

The aim is to examine whether intranasal oxytocin will influence the individuals' emotion regulation ability and related neural mechanisms.

Full description

In the present study, the investigators plan to conduct a between-subject, double-blind, placebo-controlled experiment to investigate the effects of oxytocin on neural, physiological and behavior activity related to emotion regulation. The emotion regulation ability will be assessed by emotional go-nogo task and cognitive reappraisal task. The neural activity will be explored by functional magnetic resonance imaging (fMRI). And the investigators will record participants' heart rate during fMRI to investigate the effects of oxytocin on heart rate variability in emotion regulation process.

All subjects completed a range of questionnaires measuring personality and affective traits and levels of anxiety before self-administration, including Positive and Negative Affect Schedule (PANAS) , State-Trait Anxiety Inventory (STAI) , Beck Depression Inventory (BDI), Cheek and Buss shyness Scale (CBSS), Autism Spectrum Quotient (ASQ), Empathy Quotient (EQ), Interpersonal Reactivity Index (IRI), Action Control Scale (ACS), Emotion Regulation Questionnaire (ERQ), Berkley Expressivity Questionnaire (BEQ), and so on.

Enrollment: 80 estimated patients

Sex: Male

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy subjects without past or current psychiatric or neurological disorders

Exclusion criteria

• history of head injury;
• claustrophobia;
• medical or psychiatric illness.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

Oxytocin

Experimental group

Description:

intranasal administration of oxytocin

Treatment:

Drug: Oxytocin

Placebo

Placebo Comparator group

Description:

intranasal administration of placebo

Treatment:

Drug: Placebo